| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes managemen...
Trinity Biotech stock surges on high volume after announcing increased orders for TrinScreen HIV, boosting 2024 revenue project...
TRIB: 105% | Trinity Biotech shares are trading higher after the company announced an increase in projected revenue for its Tri...
Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes managemen...
-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over ye...
https://sam.gov/opp/05464da507eb41a69c3ccf9b5030d592/view
On July 12, 2024, Trinity Biotech plc (the "Company") entered into an At the Market Offering Agreement (the "Sales ...
